Yao-Yu Wu, MD

Articles by Yao-Yu Wu, MD

Although surgery and radiotherapy are standard treatments for localized STS, the role of adjuvant chemotherapy, particularly doxorubicin, in high-grade STS is debated.

Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study

ByShiny Chih-Hsuan Wu, MD,Yao-Yu Wu, MD,Chi-Ting Liau, MD,Chih‑Hsiang Chang, MD,Shih-Chiang Huang, MD,Hsin‑Nung Shih, MD,Chun-Chieh Chen, MD, PhD

March 26th 2026

Latest Updated Articles

Single-Agent Doxorubicin Adjuvant Chemotherapy for Resectable Grade 2/3 Soft Tissue Sarcomas: A Retrospective Study
March 26th 2026

Trending on CancerNetwork

Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC

Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC

FDA Clears TriNav Advance for Expanded Liver Embolization Access

Cevostamab Combo Shows Durable Responses in R/R Multiple Myeloma

MELT-MM Regimen Yields Responses in Relapsed/Refractory Multiple Myeloma